125-OR: Disparities in Access to Sodium–Glucose Cotransporter-2 Inhibitors (SGLT2i)

Abstract

SGLT2i are shown to improve diabetes control and delay the onset of diabetes-related complications. However, socioeconomic (SES) factors may influence access to SGLT2i. We assessed trends and differences in SGLT2i prescription rates by race, ethnicity, and insurance type at a large academic medical center (AMC). Data were extracted from the electronic health records at a large AMC from January 2014 to December 2021. The study outcome was SGLT2i prescription rates over time. Race and ethnicity were classified as Non-Hispanic White (NHW), NH Black (NHB), Hispanics, and Asian/Pacific Islanders (API), and insurance type as Private, Medicare, and Medicaid. Negative binomial regressions were used to estimate the prescription rates by year. Between 2014-2021, 30,030 type 2 diabetes patients received an SGLT2i prescription, and the prescription rates increased significantly from 0.25% to 11.47%, with the rates increasing fastest in Medicare patients. Privately-insured and Medicare patients were more likely to be prescribed SGLT2i than Medicaid patients (p<0.001). NHB, and Hispanic patients were less likely to be prescribed SGLT2i than NHW and API patients (p<0.001). Although SGLT2i prescription rates increased after FDA approval, substantial variations by race, ethnicity, and insurance type exist. Future studies are needed to explore how SES factors drive observed differences in access to SGLT2i. Disclosure D.S.Zhang: None. A.Rajan: None. S.Islam: None. D.M.Charytan: Advisory Panel; Merck & Co., Inc., CSL Behring, GlaxoSmithKline plc., Consultant; Novo Nordisk, Gilead Sciences, Inc., AstraZeneca, Other Relationship; Boehringer Ingelheim and Eli Lilly Alliance, zogenix, medtronic, Research Support; Amgen Inc. A.M.Jacobson: None. J.Divers: None. Funding Doucette Innovation Fund